IPO market continues to churn with a pair of Covid-19 biotechs seeking Nasdaq, while mitochondria-focused Reneo debuts

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Biotech continues to see a huge flow of companies looking to make their public debuts as the second quarter gets underway.

Two European biotechs working on Covid-19 vaccines, Vaccitech and Valneva, both filed...

Click to view original post